Strata Critical Medical, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Q2 2026 revenue grew 60.7% to $72.5M (YoY) and 22.6% sequentially to $24.3M in Clinical segment; net loss from continuing operations was $(10.5)M (−14.5% of revenue) vs. $(3.4)M prior year, primarily due to $5.0M accelerated trademark amortization and non-cash fair value adjustments of $(5.5)M. Company completed three Clinical acquisitions in Q2 2026 (Ohio Valley Perfusion, Louisville Perfusion Services, Heart and Lung Transplant-NRP) totaling approximately $34.8M in cash, projected to add >$6M annualized Adjusted EBITDA; 2026 guidance raised to $285–295M revenue (from $260–275M) and $33–35M Adjusted EBITDA (from $29–33M).
Why this rating
Strong organic+M&A revenue growth (60.7% YoY), significant guidance raise (~11% revenue midpoint increase), three bolt-on acquisitions executed, and improving Clinical margins (26.1% gross margin) offset by GAAP losses; material relative to ~$264M market cap but integration execution and Logistics margin compression warrant caution.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.